Role of alpha-Tubulin Mutations in Lissencephaly
α-微管蛋白突变在无脑畸形中的作用
基本信息
- 批准号:7862424
- 负责人:
- 金额:$ 44.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-05 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAffinityAffinity ChromatographyArchitectureBehaviorBindingBrainCategoriesCell-Free SystemCellsCerebellumCharacteristicsCultured CellsCytoplasmic ProteinDataDefectDevelopmentDiseaseDynein ATPaseElementsEmbryoEventExtracellular Matrix ProteinsGTP BindingGenesGeneticHippocampus (Brain)Homologous GeneHumanIn VitroIndividualInsectaIntractable EpilepsyLabelLeadLesionLinkMass Spectrum AnalysisMicrotubulesMolecular ChaperonesMotorMusMuscle hypotoniaMutant Strains MiceMutationNamesNeuronal Migration DisorderNeuronsPathway interactionsPatientsPhenotypePlatelet Activating FactorPlayProcessProductionProfound Mental RetardationPropertyProtein BindingProteinsRattusReactionRoleScreening procedureSiteStructureSurfaceTestingTubulinVLDL receptorabstractingalpha Tubulinbasechaperonin CCTcohortcytosolic chaperonindevelopmental diseasedoublecortin proteinfallsgel electrophoresisin vivoinfancylissencephalymigrationmutantpolymerizationreconstitutionresearch study
项目摘要
Lissencephaly is a catastrophic developmental disease characterized by a smooth surface of the brain, four abnormal cortical layers, and a variably hypoplastic cerebellum. The condition is associated with intractable epilepsy, hypotonia, and profound mental retardation from infancy. Mutations in at least three genes – LIS1, DCX and RELN – lead to very similar defects in neuronal migration that are associated with the disease. Together, these account for about 70% of cases of lissencephaly, but the underlying cause of the remaining cases is unknown. We have recently discovered that a mutation in close proximity to the GTP binding pocket of the tuba1 α-tubulin gene causes abnormal neuronal migration events in mice that are reminiscent of lissencephaly. Indeed, screening of a cohort of patients who do not carry mutations in either LIS1, DCX or RELN has revealed that mutations in TUBA1A, the human homolog of tuba1, cause neuronal migration defects including lissencephaly and pachygyria. These data reinforce the notion that microtubule based events play a central role in neuronal migration during development, and that cortical migration disorders results from disruption of critical microtubule processes. We have found that 10 different disease-causing α-tubulin mutations fall into two categories: those that could lead to haploinsufficiency (Class I), and those that do not (Class II). 1) In the case of Class I mutations, we propose to establish the defect(s) in the heterodimer assembly pathway that lead to a diminished yield of tubulin heterodimers. To do this, we will analyze the products of in vitro folding reactions done using individual purified components (chaperones) required for de novo heterodimer assembly. 2) In the case of Class II mutations, we will test the hypothesis that disruption of key elements of microtubule behavior can occur via a mechanism in which proper interactions between α-tubulin and critical effectors of microtubule function are compromised. a) We will generate a supply of tubulin heterodimers that is homogeneous in that it will contain α- and β-subunits consisting of only a single isotype that is either wild type or mutant. b) We will compare the dynamic properties of isotypically pure wild type and mutant forms of TUBA1A.
无脑畸形是一种灾难性的发育性疾病,其特征是大脑表面光滑,四个异常的皮质层和一个发育不全的小脑。这种情况与婴儿期顽固性癫痫、肌张力减退和严重的智力迟钝有关。至少有三个基因的突变-LIS 1,DCX和CINN-导致与疾病相关的神经元迁移非常相似的缺陷。这些因素加在一起约占无脑回畸形病例的70%,但其余病例的根本原因尚不清楚。我们最近发现,tuba 1 α-tubulin基因的GTP结合口袋附近的突变导致小鼠出现异常神经元迁移事件,使人联想到无脑回畸形。事实上,对一组不携带LIS 1、DCX或PICLN突变的患者进行的筛查显示,TUBA 1A(tuba 1的人类同源物)突变会导致神经元迁移缺陷,包括无脑回畸形和巨脑回畸形。这些数据加强了这样的概念,微管为基础的事件在神经元迁移在发展过程中发挥了核心作用,皮质迁移障碍的结果从关键微管过程的中断。我们发现10种不同的致病α-微管蛋白突变分为两类:可能导致单倍不足的突变(I类)和不导致单倍不足的突变(II类)。1)在I类突变的情况下,我们建议在异源二聚体组装途径中建立缺陷,导致微管蛋白异源二聚体产量减少。为此,我们将分析使用从头异二聚体组装所需的单个纯化组分(分子伴侣)进行体外折叠反应的产物。2)在II类突变的情况下,我们将检验以下假设:微管行为的关键要素的破坏可以通过α-微管蛋白与微管功能的关键效应物之间的适当相互作用受到损害的机制发生。a)我们将产生微管蛋白异源二聚体的供应,其是同质的,因为其将含有仅由单一同种型(野生型或突变型)组成的α亚基和β亚基。B)我们将比较TUBA 1A的同种型纯野生型和突变形式的动力学性质。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mutations in the β-tubulin gene TUBB5 cause microcephaly with structural brain abnormalities.
- DOI:10.1016/j.celrep.2012.11.017
- 发表时间:2012-12-27
- 期刊:
- 影响因子:8.8
- 作者:Breuss M;Heng JI;Poirier K;Tian G;Jaglin XH;Qu Z;Braun A;Gstrein T;Ngo L;Haas M;Bahi-Buisson N;Moutard ML;Passemard S;Verloes A;Gressens P;Xie Y;Robson KJ;Rani DS;Thangaraj K;Clausen T;Chelly J;Cowan NJ;Keays DA
- 通讯作者:Keays DA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NICHOLAS COWAN其他文献
NICHOLAS COWAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NICHOLAS COWAN', 18)}}的其他基金
Tubulin Mutations in Neuronal Migration Disorders
神经元迁移障碍中的微管蛋白突变
- 批准号:
8661847 - 财政年份:2013
- 资助金额:
$ 44.74万 - 项目类别:
Tubulin Mutations in Neuronal Migration Disorders
神经元迁移障碍中的微管蛋白突变
- 批准号:
8517751 - 财政年份:2012
- 资助金额:
$ 44.74万 - 项目类别:
Tubulin Mutations in Neuronal Migration Disorders
神经元迁移障碍中的微管蛋白突变
- 批准号:
8672657 - 财政年份:2012
- 资助金额:
$ 44.74万 - 项目类别:
Tubulin Mutations in Neuronal Migration Disorders
神经元迁移障碍中的微管蛋白突变
- 批准号:
8293824 - 财政年份:2012
- 资助金额:
$ 44.74万 - 项目类别:
Inhibition of the Tubulin Folding Pathway as a Novel Therapy for Cancer
抑制微管蛋白折叠途径作为癌症的新疗法
- 批准号:
7608641 - 财政年份:2007
- 资助金额:
$ 44.74万 - 项目类别:
Inhibition of the Tubulin Folding Pathway as a Novel Therapy for Cancer
抑制微管蛋白折叠途径作为癌症的新疗法
- 批准号:
7615339 - 财政年份:2007
- 资助金额:
$ 44.74万 - 项目类别:
Inhibition of the Tubulin Folding Pathway as a Novel Therapy for Cancer
抑制微管蛋白折叠途径作为癌症的新疗法
- 批准号:
7450805 - 财政年份:2007
- 资助金额:
$ 44.74万 - 项目类别:
Inhibition of the Tubulin Folding Pathway as a Novel Therapy for Cancer
抑制微管蛋白折叠途径作为癌症的新疗法
- 批准号:
7321819 - 财政年份:2007
- 资助金额:
$ 44.74万 - 项目类别:
相似海外基金
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10506915 - 财政年份:2021
- 资助金额:
$ 44.74万 - 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10325006 - 财政年份:2021
- 资助金额:
$ 44.74万 - 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
- 批准号:
1746198 - 财政年份:2018
- 资助金额:
$ 44.74万 - 项目类别:
Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
- 批准号:
512537-2017 - 财政年份:2017
- 资助金额:
$ 44.74万 - 项目类别:
University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
- 批准号:
1404605 - 财政年份:2014
- 资助金额:
$ 44.74万 - 项目类别:
Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
- 批准号:
1263713 - 财政年份:2013
- 资助金额:
$ 44.74万 - 项目类别:
Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
- 批准号:
425749-2012 - 财政年份:2012
- 资助金额:
$ 44.74万 - 项目类别:
Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
- 批准号:
1159886 - 财政年份:2012
- 资助金额:
$ 44.74万 - 项目类别:
Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
- 批准号:
19560760 - 财政年份:2007
- 资助金额:
$ 44.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
- 批准号:
234753-2000 - 财政年份:2003
- 资助金额:
$ 44.74万 - 项目类别:
Collaborative Research and Development Grants














{{item.name}}会员




